(Q44661317)

5 December 2017

title

Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer (English)

1 reference

5 December 2017

Gyeong Hoon Kang

16

0 references

Yung-Jue Bang

6

object named as

Yung-Jue Bang

1 reference

5 December 2017

5

Seock-Ah Im

1 reference

5 December 2017

4

Do-Youn Oh

1 reference

5 December 2017

3

Sae-Won Han

1 reference

5 December 2017

20

Tae-You Kim

1 reference

5 December 2017

1

Kyung-Hun Lee

1 reference

5 December 2017

8

Keun-Wook Lee

1 reference

5 December 2017

17

Seung-Yong Jeong

1 reference

5 December 2017

19

Jae-Gahb Park

1 reference

5 December 2017

2

Hye Jung Chang

1 reference

5 December 2017

Sun Young Kim

7

1 reference

5 December 2017

Jee Hyun Kim

9

1 reference

5 December 2017

Yong Sang Hong

10

1 reference

5 December 2017

Tae Won Kim

11

1 reference

5 December 2017

Young Suk Park

12

1 reference

5 December 2017

Won Ki Kang

13

1 reference

5 December 2017

Sang Joon Shin

14

1 reference

5 December 2017

Joong Bae Ahn

15

1 reference

5 December 2017

Kyu Joo Park

18

1 reference

5 December 2017

publication date

13 January 2013

1 reference

Cancer Chemotherapy and Pharmacology

5 December 2017

published in

1 reference

5 December 2017

volume

71

1 reference

5 December 2017

issue

4

1 reference

5 December 2017

page(s)

843-851

1 reference

Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2075-3

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2075-3

Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2075-3

Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2075-3

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2075-3

Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2075-3

Pharmacogenomics--drug disposition, drug targets, and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2075-3

Pharmacogenetics in colorectal cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2075-3

Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2075-3

21 January 2018

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2075-3

Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2075-3

Safety and tolerability of FOLFOX4 in the adjuvant treatment of colon cancer in Asian patients: The MASCOT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2075-3

No association of ERCC1 C8092A and T19007C polymorphisms to cancer risk: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2075-3

Thymidylate synthase gene variations: predictive and prognostic markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2075-3

Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2075-3

Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2075-3

Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2075-3

Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2075-3

Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2075-3

A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2075-3

Cellular processing of platinum anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2075-3

A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2075-3

Nationwide cancer incidence in Korea, 2003-2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2075-3

GSTM1 and GSTT1 polymorphisms and nasopharyngeal cancer risk: an evidence-based meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2075-3

10.1007/S00280-013-2075-3

21 January 2018

Identifiers

DOI

1 reference

5 December 2017

1 reference